natgillin/translations-raw huggingface dataset:
3 ml suspension i cylinderampul (type 1 farveløs glas) med et stempel (brombutylgummi (type 1)) og ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
6. 6 Regler for desruktion og anden håndtering
6.6 Special precautions for disposal and other handling
Insulin- pen Cylinderampullerne skal anvendes i forbindelse med en insulin pen såsom OptiPen og andre penne som passer til Insulin Human Winthrop cylinderampuller, og som anbefalet i informationen fra fremstilleren af pennen.
Insulin pen The cartridges are to be used in conjunction with an insulin pen such as OptiPen and other pens suitable for Insulin Human Winthrop cartridges and as recommended in the information provided by the device manufacturer.
Hvis insulin- pennen er skadet eller ikke virker ordentligt (pga. mekaniske fejl) må den kasseres, og en ny insulin- pen tages i brug.
If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used.
Cylinderampuller Insulin Human Winthrop Comb 15 skal før det sættes ind i pennen opbevares ved stuetemperatur i 1
Cartridges Before insertion into the pen, Insulin Human Winthrop Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Dette er tilfældet, hvis fx suspensionen forbliver klar eller klumper, så partikler eller fnug findes i insulinet eller sætter sig på cylinderampullens væg eller bund.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
141 Insulin Human Winthrop Comb 15 kan blandes med alle humane insuliner fra Sanofi- Aventis, men IKKE med dem der er designet til anvendelse i insulinpumper.
Insulin Human Winthrop Comb 15 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinier
143 Any unused product or waste material should be disposed of in accordance with local requirements.
142 1.
144 1.
Insulin Human Winthrop Comb 15 100 IE/ ml injektionsvæske, suspension i en fyldt pen
Insulin Human Winthrop Comb 15 100 IU/ ml suspension for injection in a pre-filled pen.
143 Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
145 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Brugsanvisningen i indlægssedlen skal læses omhyggeligt før Optiset anvendes
Before using OptiSet, the Instructions for Use included in the Package Leaflet must be read carefully.
Patienter, der er overfølsomme over for Insulin Human Winthrop Comb 15, men hvor et bedre behandlingsalternativ ikke findes, må kun fortsætte behandlingen under særlig nøje kontrol og – om nødvendigt – i forbindelse med samtidig anti- allergisk behandling.
Patients hypersensitive to Insulin Human Winthrop Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
144 I tilfælde af utilstrækkelig glukosekontrol eller ved tendens til udvikling af hyper - eller hypoglykæmi skal følgende vurderes inden en eventuel dosisjustering: hvorvidt patienten har overholdt den ordinerede behandlingsforskrift, har fulgt forskrifterne for injektionssteder, anvendt korrekt injektionsteknik, samt hvorvidt øvrige relevante faktorer er opfyldt.
146 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
145 Anvendelse af pennen
147 Handling of the pen
146 4. 8 Bivirkninger
148 4.8 Undesirable effects
147 Sygdomme i hud og subkutane væv
Skin and subcutaneous tissue disorders
Dette forsinker den lokale insulinabsorption.
149 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
148 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
5. 2 Farmakokinetiske egenskaber
150 5.2 Pharmacokinetic properties
149 Insulin Human Winthrop Comp 15 må ikke komme i direkte berøring med frostboks eller fryseelementer.
Do not put Insulin Human Winthrop Comb 15 next to the freezer compartment or a freezer pack.
6. 5 Emballagetype og pakningsstørrelser.
151 6.5 Nature and contents of container
3 ml suspension i en cylinderampul af (type 1farveløs glas) med et stempel (brombutylgummi type 1)), ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I)).
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
Før første anvendelse skal Insulin Human Winthrop Comb 15 opbevares ved stuetemperatur i 1
Before first use, Insulin Human Winthrop Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
Dette gøres bedst ved
This is best done by gently tilting the pen back and forth (at least ten times).
Insulin Human Winthrop Comb 15 må ikke anvendes, hvis dette ikke er tilfældet, fx hvis suspensionen forbliver klar eller klumper, så partikler eller fnug findes i insulinet eller sætter sig på cylinderampullens væg eller bund.
Insulin Human Winthrop Comb 15 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the cartridge.
Insulin Human Winthrop Comb 15 må ikke blandes med nogen anden insulin eller insulinanaloger.
Insulin Human Winthrop Comb 15 must not be mixed with any other insulin or with insulin analogues.
Anvendelse af pennen Brugsanvisningen i indlægssedlen skal læses omhyggeligt før Optiset anvendes.
152 Handling of the pen The Instructions for Use included in the Package Leaflet must be read carefully before using OptiSet.
Nål (ikke inkluderet)
Schematic diagram of the pen
Skematisk diagram af pennen 150 Vigtig information vedrørende anvendelse af pennen: • Sæt altid en ny nål på pennen før den anvendes.
Important information for use of OptiSet: • Always attach a new needle before each use.
Brug kun nåle som er kompatible med OptiSet. • Udfør altid sikkerhedstesten før hver injektion. • Hvis der anvendes en ny OptiSet, skal sikkerhedstesten udføres med de 8 enheder, som er forudindstillet af fremstilleren. • Dosisskalaen kan kun drejes i en retning. • Dosiskalaen (ændring af dosis) må aldrig drejes efter dosisknappen er trukket ud. • Denne pen må kun anvendes af patienten.
Only use needles that are compatible for use with OptiSet. • Always perform the safety test before each injection. • If a new OptiSet is used the initial safety test must be done with the 8 units preset by the manufacturer. • The dosage selector can only be turned in one direction. • Never turn the dosage selector (change the dose) after injection button has been pulled out. • This pen is only for the patients use.
Trin 2.
153 Step 2.
151 Ved en OptiSet der allerede er taget i brug, vælges en dosis på 2 enheder ved at dreje dosisskalaen fremad indtil doseringspilen peger på 2.
In-use OptiSet, select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
Trin 6.
154 Step 6.
152 Efter hver injektion skal nålen tages af og kasseres.
The needle should be removed after each injection and discarded.
153 1.
155 1.
Injektionsvæske, suspension i cylinderampul til OptiClik.
Suspension for injectionin a cartridge for OptiClik.
Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
156 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Insulin Human Winthrop Comb 15 i cylinderampuller er udviklet kun til brug i penne af typen OptiClik.
Insulin Human Winthrop Comb 15 in cartridges for OptiClik has been developed for use with OptiClik only.
Hos patienter med svært nedsat leverfunktion kan insulinbehovet mindskes på grund af nedsat evne til glukoneogenese og nedsat insulinmetabolisme.
157 In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
155 I tilfælde af utilstrækkelig glukosekontrol eller ved tendens til udvikling af hyper - eller hypoglykæmi skal følgende vurderes inden en eventuel dosisjustering: hvorvidt patienten har overholdt den ordinerede behandlingsforskrift, har fulgt forskrifterne for injektionssteder, anvendt korrekt injektionsteknik, samt hvorvidt øvrige relevante faktorer er opfyldt.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
Interkurrente sygdomme
158 Intercurrent illness
156 4. 5 Interaktion med andre lægemidler og andre former for interaktion
4.5 Interaction with other medicinal products and other forms of interaction
Patienter bør rådes til at tage forholdsregler for at undgå hypoglykæmi i forbindelse med bilkørsel.
159 Patients should be advised to take precautions to avoid hypoglycaemia whilst driving.
157 4. 8 Bivirkninger
4.8 Undesirable effects
158 Sygdomme i hud og subkutane væv
160 Skin and subcutaneous tissue disorders
159 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
5. 2 Farmakokinetiske egenskaber
161 5.2 Pharmacokinetic properties
Insuma Comb 15 må ikke komme i direkte berøring med frostbokse eller fryseelementer.
Do not put Insulin Human Winthrop Comb 15 next to the freezer compartment or a freezer pack.
160 Cylinderampuller i brug:
In-use cartridges:
6. 5 Emballagetype og pakningsstørrelser.
162 6.5 Nature and contents of container
3 ml suspension i en cylinderampul (type 1 farveløs glas) med et stempel (brombutylgummi (type 1)) og en hætte (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type 1)).
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
Cylinderampuller Insulin Human Winthrop Comb 15 skal opbevares ved stuetemperatur i 1 - 2 timer før det sættes ind i pennen, og herefter rystes op for at kontrollere suspensionen.
Cartridges Before insertion into the pen, Insulin Human Winthrop Comb 15 must be kept at room temperature for 1 to 2 hours and then resuspended to check the contents.
161 Insulin Human Winthrop Comb 15 kan blandes med alle humane insuliner fra Sanofi- Aventis, men IKKE med dem der er designet til anvendelse i insulinpumper.
Insulin Human Winthrop Comb 15 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Human Winthrop Comb 15 cylinderampuller til OptiClik er ikke beregnet til, at andre insuliner kan iblandes i cylinderampullen til OptiClik.
163 Insulin Human Winthrop Comb 15 cartridges for OptiClik are not designed to allow any other insulin to be mixed in the cartridge for OptiClik.
EU/ 1/ 06/ 368/ 070EU/ 1/ 06/ 368/ 071 EU/ 1/ 06/ 368/ 072 EU/ 1/ 06/ 368/ 073 EU/ 1/ 06/ 368/ 074 EU/ 1/ 06/ 368/ 075
EU/ 1/ 06/ 368/ 070 EU/ 1/ 06/ 368/ 071 EU/ 1/ 06/ 368/ 072 EU/ 1/ 06/ 368/ 073 EU/ 1/ 06/ 368/ 074 EU/ 1/ 06/ 368/ 075
162 1.
164 1.
SoloStar
SoloStar.
SoloStar doserer insulin i trin på 2 IE op til en maksimal engangsdosis på 40 IE.
Each pen contains multiple doses.
163 Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
165 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Brugsanvisningen i indlægssedlen skal læses omhyggeligt før SoloStar anvendes
Before using SoloStar, the Instructions for Use included in the Package Leaflet must be read carefully.
164 I tilfælde af utilstrækkelig glukosekontrol eller ved tendens til udvikling af hyper - eller hypoglykæmi skal følgende vurderes inden en eventuel dosisjustering: hvorvidt patienten har overholdt den ordinerede behandlingsforskrift, har fulgt forskrifterne for injektionssteder, anvendt korrekt injektionsteknik, samt hvorvidt øvrige relevante faktorer er opfyldt.
166 In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
165 Anvendelse af pennen
167 Handling of the pen
166 4. 8 Bivirkninger
168 4.8 Undesirable effects
167 Sygdomme i hud og subkutane væv
Skin and subcutaneous tissue disorders
Dette forsinker den lokale insulinabsorption.
169 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
168 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
5. 2 Farmakokinetiske egenskaber
170 5.2 Pharmacokinetic properties
Insuman Comp 15 må ikke komme i direkte berøring med frostboks eller fryseelementer.
Do not put Insulin Human Winthrop Comb 15 next to the freezer compartment or a freezer pack.
169 Opbevar pennen i den ydre karton for at beskytte mod lys.
Keep the pre-filled pen in the outer carton in order to protect from light.
6. 5 Emballagetype og pakningsstørrelser.
171 6.5 Nature and contents of container
3 ml suspension i en cylinderampul af (type 1farveløs glas) med et stempel (brombutylgummi type 1)), ombøjet låg (aluminium) med en prop (bromobutyl eller laminate af polyisoprene og bromobutylgummi (type I))..
3 ml suspension in a cartridge (type 1 colourless glass) with a plunger (bromobutyl rubber (type 1)) and a flanged cap (aluminium) with a stopper (bromobutyl or laminate of polyisoprene and bromobutyl rubber (type 1)).
170 Anveldelse af pennen.
172 Handling of the pen
171 • Insulinopløsningen (Insulin Human Winthrop Rapid) skal være klar, farveløs, uden synlige partikler og skal have en vandlignende konsistens.
After removing the pen cap, the appearance of the insulin should also be checked: • The insulin solution (Insulin Human Winthrop Rapid) must be clear, colourless, with no solid particles visible, and must have a water-like consistency.
Trin 2.
173 Step 2.
172 7.
7.
173 1.
175 1.
Insulin Human Winthrop Comb 25 - 100 IE/ ml injektionsvæske, suspension, i hætteglas
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a vial
Hver ml indeholder 100 IE human insulin (svarende til 3, 5 mg) af.
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
Human insulin 25 fremstilles med rekombinant DNA- teknologi i Escherichia coli.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
176 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Insulin Human Winthrop Comb 25 indeholder 100 IE insulin pr. ml suspension.
Insulin Human Winthrop Comb 25 contains 100 IU of insulin per ml suspension.
For yderligere information om håndtering, se pkt 6. 6.
For further details on handling, see section 6.6.
Insulin Human Winthrop Comb 25 må ikke gives intravenøst og må ikke anvendes i infusionspumper og i eksterne eller implanterede insulinpumper.
Insulin Human Winthrop Comb 25 must not be administered intravenously and must not be used in infusion pumps or external or implanted insulin pumps.
Patienter, der er overfølsomme over for Insulin Human Winthrop Comb 25, men hvor et bedre behandlingsalternativ ikke findes, må kun fortsætte behandlingen under særlig nøje kontrol og - om nødvendigt - i forbindelse med samtidig anti- allergisk behandling.
Patients hypersensitive to Insulin Human Winthrop Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Hos patienter med nedsat nyrefunktion kan insulinbehovet være reduceret på grund af nedsat insulinmetabolisme.
177 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
175 Hos patienter med svært nedsat leverfunktion kan insulinbehovet mindskes på grund af nedsat evne til glukoneogenese og nedsat insulinmetabolisme.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Interkurrente sygdomme
178 Intercurrent illness
176 4. 5 Interaktion med andre lægemidler og andre former for interaktion
4.5 Interaction with other medicinal products and other forms of interaction
Insulin Human Winthrop Comb 25 kan anvendes under amning..
Insulin Human Winthrop Comb 25 can be used during breastfeeding.
177 4. 8 Bivirkninger
179 4.8 Undesirable effects
178 Sygdomme i hud og subkutane væv
Skin and subcutaneous tissue disorders
Dette forsinker den lokale insulinabsorption.
180 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
179 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
5. 2 Farmakokinetiske egenskaber
181 5.2 Pharmacokinetic properties
180 Opbevar hætteglasset i den ydre karton for at beskytte mod lys.
Keep the vial in the outer carton in order to protect from light.
6. 5 Emballagetype og pakningsstørrelser
182 6.5 Nature and contents of container
5 ml suspension i hætteglas (type 1 af farveløs glas) med ombøjet hætte (aluminium), en prop (chlorbutylgummi (type 1)) og aftageligt låg (polypropylen).
5 ml suspension in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
Efter omrystning skal væsken have et homogent, mælkehvidt udseende, ellers må Insulin Human Winthrop Comb 25 ikke anvendes.
After resuspension, the fluid must have a uniformly milky appearance.
Dette er tilfældet, hvis fx suspensionen forbliver klar, eller klumper, så partikler eller fnug findes i insulinet eller sætter sig på glassets væg eller bund.
Insulin Human Winthrop Comb 25 must not be used if this cannot be achieved, i. e. if the suspension remains clear, for example, or if clumps, particles or flocculation appear in the insulin or stick to the wall or bottom of the vial.
Insulin Human Winthrop Comb 25 må i lighed med andre insulinpræparater ikke blandes med opløsninger, der indeholder reducerende stoffer som thioler og sulfitter.
As with all insulin preparations, Insulin Human Winthrop Comb 25 must not be mixed with solutions containing reducing agents such as thioles and sulphites.
Insulin Human Winthrop Comb 25 kan blandes med alle humane insuliner fra Sanofi- Aventis, men IKKE med dem der er designet til anvendelse i insulinpumper.
Insulin Human Winthrop Comb 25 may be mixed with all Sanofi-Aventis human insulins, but NOT with those designed specifically for use in insulin pumps.
Insulin Comb 25 må heller IKKE blandes med insuliner af animalsk oprindelse eller med insulinanaloger.
Insulin Human Winthrop Comb 25 must also NOT be mixed with insulins of animal origin or with insulin analogues.
Injektion tbør foretages umiddelbart efter blandingen.
It is advisable to inject immediately after mixing.
EU/ 1/ 06/ 368/ 038
EU/ 1/ 06/ 368/ 038 EU/ 1/ 06/ 368/ 039
182 1.
184 1.
Insulin Human Winthrop Comb 25 40 IE/ ml injektionsvæske, suspension, i hætteglas
Insulin Human Winthrop Comb 25 40 IU/ ml suspension for injection in a vial
Hver ml indeholder 40 IE human insulin (svarende til 1, 4 mg) af det aktive stof insulin human.
Each ml contains 40 IU insulin human (equivalent to 1.4 mg).
Human insulin fremstilles med rekombinant DNA- teknologi i Escherichia col..
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
185 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Insulin Human Winthrop Comb 25 indeholder 40 IE insulin pr. ml suspension.
Insulin Human Winthrop Comb 25 contains 40 IU of insulin per ml suspension.
For yderligere information om håndtering, se pkt. 6. 6.
For further details on handling, see section 6.6.
Hos patienter med nedsat nyrefunktion kan insulinbehovet være reduceret på grund af nedsat insulinmetabolisme.
186 In patients with renal impairment, insulin requirements may be diminished due to reduced insulin metabolism.
184 Hos patienter med svært nedsat leverfunktion kan insulinbehovet mindskes på grund af nedsat evne til glukoneogenese og nedsat insulinmetabolisme.
In patients with severe hepatic impairment, insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism.
Interkurrente sygdomme
187 Intercurrent illness
185 4. 5 Interaktion med andre lægemidler og andre former for interaktion
4.5 Interaction with other medicinal products and other forms of interaction
Insulin Human Winthrop Comb 25 kan anvendes under amning.
Insulin Human Winthrop Comb 25 can be used during breastfeeding.
186 4. 8 Bivirkninger
188 4.8 Undesirable effects
187 Sygdomme i hud og subkutane væv
Skin and subcutaneous tissue disorders
Dette forsinker den lokale insulinabsorption.
189 As with any insulin therapy, lipodystrophy may occur at the injection site and delay local insulin absorption.
188 Farmakodynamiske karakteristika
Pharmacodynamic characteristics
5. 2 Farmakokinetiske egenskaber
190 5.2 Pharmacokinetic properties
189 Opbevar hætteglasset i den ydre karton for at beskytte mod lys.
Keep the vial in the outer carton in order to protect from light.
6. 5 Emballage (art og indhold)
191 6.5 Nature and contents of container
10 ml suspension i et hætteglas (type 1 farveløs glas) med ombøjet hætte (aluminium), en prop (chlorbutylgummi (type 1)) og aftageligt låg (polypropylen).
10 ml suspension in a vial (type 1 colourless glass) with a flanged cap (aluminium), a stopper (chlorobutyl rubber (type 1)) and a tear-off cap (polypropylene).
190 Ikke anvendte lægemidler samt affald heraf bør destrueres i henhold til lokale retningslinier.
Any unused product or waste material should be disposed of in accordance with local requirements.
191 1.
193 1.
Insulin Human Winthrop Comb 25 100 IE/ ml injektionsvæske, suspension, i cylinderampul
Insulin Human Winthrop Comb 25 100 IU/ ml suspension for injection in a cartridge
Injektionsvæske, suspension i cylinderampul.
Suspension for injection in a cartridge.
Efter omstilling fra animalsk til human insulin vil dosisreduktion især være påkrævet hos patienter, der:
194 Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
192 Omhyggelig metabolisk kontrol er nødvendig ved præparatomstilling og i de første uger lige efter.
Close metabolic monitoring is recommended during the transition and in the initial weeks thereafter.
Insulin Human Winthrop Comb 25 i cylinderampuller er udviklet til brug i penne af typen OptiPen.
Insulin Human Winthrop Comb 25 in cartridges has been developed for use in the OptiPen series.